Abstract:Background and aims: Vascular smooth muscle cell (VSMC) dedifferentiation contributes to neointima formation, which results in various vascular disorders. Intermedin (IMD), a cardiovascular paracrine/autocrine polypeptide, is involved in maintaining circulatory homeostasis. However, whether IMD protects against neointima formation remains largely unknown. The purpose of this study is to investigate the role of IMD in neointima formation and the possible mechanism. Methods: IMD1-53 (100ng/kg/h) or saline water was used on rat carotid-artery balloon-injury model. The mouse left common carotid-artery ligation-injury model was established using IMD-transgenic and C57BL/6J mice. Immunohistochemistry and immunofluorescence staining was used to detect the protein expression in rat carotid arteries. Radioimmunoassay was used to determine the serum IMD level. The hematoxylin andeosin staining was used for carotid arteries morphological testing. In vitro, for rat primary cultured VSMC phenotype transition, proliferation and migration assays, platelet-derived growth factor-BB (PDGF-BB) reagent and IMD1-53 peptide were added to the culture media at the final concentration of 20 ng/mL and 10-7mol/L respectively. Quantification of VSMC proliferation involved MTT and BrdU assay and migration was detected by wound-healing assay. Western blot and realtime PCR were used to detect the protein and mRNA levels of tissues or cells. Results: With the rat carotid-artery balloon-injury model, IMD was significantly downregulated in injured arteries and plasma. Exogenous IMD1-53 greatly inhibited neointima formation and prevented VSMC from switching to a synthetic phenotype. With the left common carotid-artery ligation-injury model, IMD-transgenic mice showed less neointima formation than C57BL/6J mice. PDGF-BB reduced IMD mRNA expression in rat primary cultured VSMCs but increased that of its receptors, calcitonin receptor-like receptor or receptor activity-modifying proteins. Furthermore, PDGF-BB promoted VSMC proliferation and migration and transformed VSMCs to the synthetic phenotype, which was reversed with IMD1-53 treatment. Mechanistically, IMD1-53 maintained the contractile VSMC phenotype via the cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) pathway. Conclusions: IMD attenuated neointima formation both in the rat model of carotid-artery balloon injury and mouse model of common carotid-artery ligation injury. IMD protection may be mediated by maintaining a VSMC contractile phenotype via the cAMP/PKA pathway.

INTERMEDIN1-53 AMELIORATES HOMOCYSTEINE-PROMOTED ATHEROSCLEROTIC CALCIFICATION BY INHIBITING ENDOPLASMIC RETICULUM STRESS

Intermedin(1-53) Protects Against Myocardial Fibrosis by Inhibiting Endoplasmic Reticulum Stress and Inflammation Induced by Homocysteine in Apolipoprotein E-Deficient Mice

Intermedin1-53 attenuates vascular smooth muscle cell calcification by inhibiting endoplasmic reticulum stress via cyclic adenosine monophosphate/protein kinase A pathway

Intermedin Ameliorates Atherosclerosis in Apoe Null Mice by Modifying Lipid Profiles

Intermedin1-53 attenuates aging-associated vascular calcification in rats by upregulating sirtuin 1

Intermedin1-53 Attenuates Atherosclerotic Plaque Vulnerability by Inhibiting CHOP-mediated Apoptosis and Inflammasome in Macrophages.

Interference in mevalonate pathway ameliorates homocysteine-induced endothelium-dysfunction.

Intermedin Ameliorates Atherosclerosis by Increasing Cholesterol Efflux Through the Camp-Pka Pathway in Macrophage RAW264.7 Cell Line

Intermedin Alleviates Vascular Calcification in CKD Through Sirtuin 3-Mediated Inhibition of Mitochondrial Oxidative Stress

Intermedin inhibits vascular calcification by increasing the level of matrix gamma-carboxyglutamic acid protein

Intermedin Restores Hyperhomocysteinemia-induced Macrophage Polarization and Improves Insulin Resistance in Mice

Increased Stability of Phosphatase and Tensin Homolog by Intermedin Leading to Scavenger Receptor A Inhibition of Macrophages Reduces Atherosclerosis in Apolipoprotein E-deficient Mice

Intermedin1-53 protects against cardiac hypertrophy by inhibiting endoplasmic reticulum stress via activating AMP-activated protein kinase

Intermedin1–53 Attenuates Vascular Calcification in Rats with Chronic Kidney Disease by Upregulation of Α-Klotho

Intermedin alleviates diabetic vascular calcification by inhibiting GLUT1 through activation of the cAMP/PKA signaling pathway

Endogenous Intermedin Protects Against Intimal Hyperplasia by Inhibiting Endoplasmic Reticulum Stress.

Intermedin1-53 Attenuates Abdominal Aortic Aneurysm by Inhibiting Oxidative Stress

Hypercholesterolemia Up-Regulates the Expression of Intermedin and Its Receptor Components in the Aorta of Rats Via Inducing the Oxidative Stress

Intermedin reduces neointima formation by regulating vascular smooth muscle cell phenotype via cAMP/PKA pathway

Effects of intermedin1-53 on myocardial fibrosis

Abstract 319: Intermedin Attenuates Vascular Calcification by Upregulating Klotho Via CRLR/RAMP3 Receptor Complex and Camp/pka Signaling Pathway in Rats with Chronic Kidney Disease